IPO
IPO filing, visualized

Retension Pharmaceuticals, Inc.

RTSN · Nasdaq424B4 · Oct 9, 2026Priced Oct 8, 2026

Priced Oct 8, 2026 · range was $11–$13 · latest SEC filing Nov 4, 2026.

Pinch-zoom for details.

The offering

Final price
$12.00
per share, from the final prospectus
Shares offered
3.75M
sold by the company
Raise at the final price
$45.0M
3,750,000 × $12, before fees
Net proceeds (company est.)
$38.9M
at $12 a share

What the company does

Clinical-stage drug developer focused on high blood pressure; its candidate RTN-001 is a once-daily oral PDE-5 inhibitor.

Operating result

Fiscal year

1st half

Net result

Fiscal year

1st half

Things to weigh

  • Loss-making: net loss of $7.53M in H1 2026.

The numbers

$FY2024FY2025YoYH1 2025H1 2026Change
Operating result(2.28M)(6.88M)−202%(2.11M)(7.79M)−269%
Net result(1.91M)(6.30M)−230%(1.89M)(7.53M)−299%
$FY2024FY2025YoY
Operating result(2.28M)(6.88M)−202%
Net result(1.91M)(6.30M)−230%
$H1 2025H1 2026Change
Operating result(2.11M)(7.79M)−269%
Net result(1.89M)(7.53M)−299%

Values as filed, shortened (K = thousand, M = million, B = billion); losses in parentheses. Change columns compare each period with the same period a year earlier; a bigger loss shows as a negative change. Green is better for the company, red worse; n/m where the sign flips.

Risks

  1. We have a limited operating history, have incurred significant operating losses since our inception…
  2. Our recurring losses from operations and financial condition raise substantial doubt about our ability to continue as a going concern…
  3. We will require substantial additional capital to finance our goals, and a failure to obtain this necessary capital when needed on acceptable terms…
  4. We will need to develop and expand our organization, and we may encounter difficulties in managing our growth…
  5. We are dependent on the services of our management and other clinical and scientific personnel, and if we are not able to retain these individuals…
  6. Our CEO and CSO have significant responsibilities outside of the Company, which may divert their time and attention from our business…

The filing's own risk-factor headings, shortened.

Strategy

  1. Advance RTN-001 through clinical development for the treatment of hypertension
  2. Explore combination treatments of RTN -001 with approved generic or off patent molecules
  3. Opportunistically evaluate strategic partnerships to maximize the value of RTN -001
  4. Selectively evaluate opportunities to expand our pipeline beyond RTN -001

The filing's own strategy headings, shortened.

Source: Retension Pharmaceuticals, Inc.'s Form 424B4, filed with the SEC on Oct 9, 2026 (final prospectus). Figures are as filed; changes are worked out from them. Not investment advice.

10KDecoder10KDecoder.com

10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.